The global spinal cord stimulation market size was valued at USD 2.1 billion in 2020 and is projected to reach USD 4.28 billion by 2030 at a CAGR of 8.26% from 2022 to 2030.
The spinal cord stimulator (SCS), also called the dorsal column stimulator, is a neuromodulation tool that is implanted in the body to treat chronic pain. By emitting electric signals that block pain signals, the device stops the brain from being able to perceive pain. The spinal cord stimulator is also known as the dorsal column stimulator (DCS) (SCS). A generator of electric pulses is a component of the system. Pain management therapy is the foundation of the spinal cord stimulator's operation. The spinal cord stimulator prevents the brain from receiving pain signals, hence stopping the brain from experiencing pain. In cases of sciatica, cervical radiculopathy, failed back surgery syndrome (FBSS), reflex sympathetic dystrophy, and arachnoiditis, the device has positive, symptomatic, and long-term outcomes. After an injury, CRPS is a persistent pain disorder that affects one limb (hand, arm, leg, or foot).
There are two different varieties of it: CRPS-I and CRPS-II. People with CRPS-I do not have a verified nerve injury, while those with CRPS-II have a confirmed nerve injury. The National Institute of Neurological Disorders and Stroke (NINDS) reports that women are more likely than males to experience CRPS symptoms, which can happen at any age. 90% of the time, CRPS is brought on by trauma or injury. Thus, the market's expansion is fueled by the rising number of people with chronic pain. By altering and inhibiting pain impulses before they reach the brain, it is used to treat chronic pain. The National Center for Biotechnology Information (NCBI) claims that electrical stimulation of the spinal cord's dorsal surface, which reduces neuropathic pain, is essential to the therapy of spinal cord stimulation.
|Market Size||USD 4.28 billion by 2030|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
The spinal cord stimulators market has expanded quickly due to the spinal cord stimulators, especially when compared to traditional medical management. After three years, the effectiveness of spinal cord stimulation has been established, and this results in a visibly improved quality of life.
The cost-effectiveness of spinal cord stimulators is anticipated to play a significant role during the projection period as many nations, including the U.S., move towards the accountable care model. Spinal cord stimulators are significantly more cost-effective than traditional medical therapy for the treatment of chronic pain, according to a study undertaken by scientists from the Department of Neurology at the University of Saskatchewan in Canada.
One of the numerous advantages of spinal cord stimulators is that they can help patients with chronic pain reduce their dependence on opioid medications. Particularly in the U.S., a troubling pattern of drug and opioid consumption has emerged that the government now recognizes as a public health pandemic. In order to lessen the load of narcotic prescriptions, the medical community has been forced to look for creative solutions.
Spinal cord stimulators are expected to become more popular as a preferred alternative for treating patients with chronic pain as a result of the desire to reduce the usage of opioid analgesics. This need is a key driver for the growth of the spinal cord stimulators market. Spinal cord stimulators can lessen the need for the use of opioid analgesics, according to a study presented at the North American Neuromodulation Society (NANS) annual meeting in 2017.
To reduce the size of the spinal cord stimulators, the makers have expanded their research efforts. For instance, the size of the current Implantable Pulse generator (IPG) on the market is approximately 5% smaller than the Freedom SCS system developed by Stimwave LCC. This is fueling the expansion of the spinal cord stimulation business and impulse production improvements. Differential Target Multiplexed (DTM) SCS is a brand-new Swaveform created by Stimgenics, a firm with headquarters in the United States. In January 2020, Medtronic bought the business. Research comparing Differential Target Multiplexed (DTM) SCS to traditional ones revealed a considerable reduction in pain.
The largest obstacle to the market's expansion for spinal cord stimulators is their high price, as it is with the majority of cutting-edge medical products. It is particularly difficult in areas like the Middle East & Africa, and the Asia Pacific, where treatment and device costs are not covered by reimbursement companies because the cost of the device itself, the operation, and maintenance are far from insignificant. Because of this, North America and Europe have the greatest markets for spinal cord stimulators.
Less than 10% of eligible patients are being treated with this cutting-edge technology, which shows how underdeveloped the spinal cord stimulators industry is. Since spinal cord stimulators are so expensive, only a small number of countries outside of North America and Europe have adopted them. About 85% of the world's spinal cord stimulator sales are currently concentrated in the United States and Europe, but the development of more modern, reasonably priced devices may greatly increase the viability of spinal cord stimulators in developing nations.
Due to an increase in cases of chronic pain, failing back syndrome, and CRPS, North America held the top spot in the global market in 2021 and is predicted to continue to rise rapidly in the coming years. The availability of highly qualified doctors, the presence of well-established healthcare facilities, and growing knowledge of spinal cord stimulation therapy will also propel the local market. Market expansion is also anticipated to be aided by the rapid adoption of cutting-edge technology.
Additionally, rising payments for technological advancements in equipment, including wireless remote control, are having a beneficial impact on the expansion of the industry in the area. Due to the rising number of patients experiencing neuropathic pain following spinal procedures and chronic pain in the legs, arms, and feet due to trauma and injuries, Asia Pacific is anticipated to see the highest CAGR.
In terms of revenue, Europe is predicted to be the second-largest area in 2022. Boston Scientific's introduction of the Spectra WaveWriter spinal cord stimulator device in January 2019 is anticipated to accelerate European market expansion. In addition, it is projected that the market in Europe will grow as degenerative disc diseases and chronic pain become more common.
Along with other regions, the Middle East, Africa, and Latin America have tremendous growth potential and are expected to become profitable markets. The expansion of the market in other parts of the world is influenced by factors such as the rising prevalence of chronic back pain and the rising demand for minimally invasive therapies.
This market can be segmented on the basis of products, applications, regions and competitors. Due to their affordability, adaptability, and ability to regulate pain and use wireless remotes, rechargeable devices are anticipated to see the quickest rate of growth throughout the course of the projected period. The neuropathic pain is blocked by such a gadget by sending light electrical signals to the spinal cord close to painful locations. It includes a replaceable battery that may be done easily through surgery.
Due to the increased incidence of persistent back pain and the rising number of unsuccessful back procedures, the non-rechargeable market is projected to expand. In addition, it is anticipated that increased attempts to extend the battery life of non-rechargeable stimulators will fuel market expansion. For instance, Abbott announced introducing the Proclaim XR recharge-free SCS system in September 2019. This system has a 10-year lifespan.
Additional factors supporting the segment's growth include the rise in individuals experiencing chronic and neuropathic pain as well as new product introductions by significant corporations. The Precision Novi spinal cord stimulator, an implantable pulse generator, was introduced by Boston Scientific in June 2015. (IPG). The primary cell spinal cord stimulator implant is made to improve patient comfort and treat chronic pain, which is one of the main reasons people have spine surgery.
Since there are so many people with chronic pain, the CRPS segment dominates the spinal cord stimulation device market. The warmth and color of their skin also fluctuate for those with CRPS. Due to aberrant microcirculation brought on by nerve injury controlling blood flow and temperature, all of these changes take place. Some people experience trauma or injury, such as sprains, fractures, immobilization of limbs, or soft tissue damage, which can lead to the development of CRPS. Inflammatory substances prevalent in tissues also affect the immune system. A growing number of cases of degenerative disc disease are expected to make this category increase at the fastest rate during the projection period.
It is mostly an age-related disorder that causes pain when one or more of the discs that separate the spinal column from the vertebrae degenerate or rupture. Growth in the segment is also projected to be boosted by the creation of new products and technical developments. As an illustration, the implantable neurostimulation device from Medtronic is intended to lessen the discomfort in the trunk or limbs that is chronic. CRPS, peripheral causalgia, epidural fibrosis, failed disc surgery, failed back syndrome, and post-laminectomy pain is all conditions it is used to treat.